DarioHealth (NSDQ:DRIO) said today it inked a joint marketing agreement with Glytec through which DarioHealth’s smart glucose meter will be able to transmit information to Glytec’s Glucommander Outpatient software.
Israel-based DarioHealth said that blood glucose data from its Dario Blood Glucose Monitoring System will now be imported into the Glucommander Outpatient for use in conjunction with other clinical data to create personalized insulin dose recommendations.
“The Dario Blood Glucose Monitoring System is growing in popularity among people with both Type 1 and Type 2 diabetes, and we are pleased to be able to add DarioHealth to our best-in-class network of connected device partners. Glytec doesn’t make devices, we make devices better by adding the missing element, which is insulin titration. There is little that can be done to achieve and sustain significant A1c improvements with data alone, but by making that data actionable and making timely insulin dose adjustments, we see average reductions in A1c of 2.7% points and higher over 12 months,” Glytec prez & CEO Bob Leonard said in a prepared statement.
DarioHealth touted that its Blood Glucose Monitoring System features an all-in-one smart glucose meter, a personal diabetes progress monitor, on-demand data sharing, emergency hypoglycemia alerts and a GPS locator and a carbohydrate counting tool.
“Glytec will benefit from real-time, accurate blood glucose data to provide insulin titration decision support, and we are convinced that the Dario Blood Glucose Monitoring System will be a more complete solution when paired with Glucommander Outpatient. We believe that people with diabetes need this synergy to be most successful in managing their diabetes,” DarioHealth CEO Erez Raphael said in a press release.
In January, DarioHealth said that it inked a deal with healthcare products provider Better Living Now for the distribution of its blood glucose monitoring system and the DarioEngage digital health program.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.